It was winner-takes-all in biotech investing in 2024. Larger funds attracted an outsize share of the available investment cash. While many companies struggled, dozens raised at least $100mn.
Much of the excitement was generated by red-hot sectors. In late April San Francisco-based artificial intelligence drug discovery start-up Xaira announced it had raised $1bn in one of biotech’s biggest-ever launches. New York-based weight loss start-up Metsera brought in more than $500mn in funding in seven months.
您已閱讀17%（506字），剩余83%（2387字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。